• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二肽衍生炔烃作为半胱氨酸组织蛋白酶的高效和选择性不可逆抑制剂。

Dipeptide-Derived Alkynes as Potent and Selective Irreversible Inhibitors of Cysteine Cathepsins.

机构信息

Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.

Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, Mommsenstraße 4, 01069 Dresden, Germany.

出版信息

J Med Chem. 2023 Mar 23;66(6):3818-3851. doi: 10.1021/acs.jmedchem.2c01360. Epub 2023 Mar 3.

DOI:10.1021/acs.jmedchem.2c01360
PMID:36867428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10041539/
Abstract

The potential of designing irreversible alkyne-based inhibitors of cysteine cathepsins by isoelectronic replacement in reversibly acting potent peptide nitriles was explored. The synthesis of the dipeptide alkynes was developed with special emphasis on stereochemically homogeneous products obtained in the Gilbert-Seyferth homologation for C≡C bond formation. Twenty-three dipeptide alkynes and 12 analogous nitriles were synthesized and investigated for their inhibition of cathepsins B, L, S, and K. Numerous combinations of residues at positions P1 and P2 as well as terminal acyl groups allowed for the derivation of extensive structure-activity relationships, which were rationalized by computational covalent docking for selected examples. The determined inactivation constants of the alkynes at the target enzymes span a range of >3 orders of magnitude (3-10 133 M s). Notably, the selectivity profiles of alkynes do not necessarily reflect those of the nitriles. Inhibitory activity at the cellular level was demonstrated for selected compounds.

摘要

研究了通过在可逆作用的强肽腈中进行等电子取代来设计半胱氨酸组织蛋白酶不可逆炔抑制剂的潜力。特别强调了立体化学均匀产物的二肽炔的合成,这些产物是通过 Gilbert-Seyferth 同系化反应获得的,用于 C≡C 键形成。合成了 23 种二肽炔和 12 种类似的腈,并研究了它们对组织蛋白酶 B、L、S 和 K 的抑制作用。在位置 P1 和 P2 以及末端酰基上的许多残基组合允许得出广泛的构效关系,通过对选定实例的计算共价对接对其进行了合理化。在靶酶中,炔的失活常数的范围跨越了 3 个数量级以上(3-10133 M s)。值得注意的是,炔的选择性谱不一定反映出腈的选择性谱。已证明选定化合物在细胞水平上具有抑制活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/4a184a239aec/jm2c01360_0019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/a28667e1f4d3/jm2c01360_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/9540e2b27525/jm2c01360_0020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/97de2abff8af/jm2c01360_0021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/a38cef74ce0e/jm2c01360_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/a4b09cf0e30c/jm2c01360_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/68f1145964ce/jm2c01360_0022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/5f2fbdab0ff1/jm2c01360_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/f80891252d8e/jm2c01360_0023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/2684f69c4fea/jm2c01360_0024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/d31bde7566e2/jm2c01360_0025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/0abef7e16c49/jm2c01360_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/8df927df0d87/jm2c01360_0026.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/f2208beeb15b/jm2c01360_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/9d8f4a02b67e/jm2c01360_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/1673706fdc87/jm2c01360_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/d644d2a730be/jm2c01360_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/05bdbbbbd605/jm2c01360_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/d68f7ea8f6d7/jm2c01360_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/a2fad23bc7f0/jm2c01360_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/964d42204d56/jm2c01360_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/4fd047250b90/jm2c01360_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/58c69f78ad9f/jm2c01360_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/d756cbc09fc1/jm2c01360_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/f88e7a4d89d8/jm2c01360_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/164fa7c8a45f/jm2c01360_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/4a184a239aec/jm2c01360_0019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/a28667e1f4d3/jm2c01360_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/9540e2b27525/jm2c01360_0020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/97de2abff8af/jm2c01360_0021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/a38cef74ce0e/jm2c01360_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/a4b09cf0e30c/jm2c01360_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/68f1145964ce/jm2c01360_0022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/5f2fbdab0ff1/jm2c01360_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/f80891252d8e/jm2c01360_0023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/2684f69c4fea/jm2c01360_0024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/d31bde7566e2/jm2c01360_0025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/0abef7e16c49/jm2c01360_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/8df927df0d87/jm2c01360_0026.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/f2208beeb15b/jm2c01360_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/9d8f4a02b67e/jm2c01360_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/1673706fdc87/jm2c01360_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/d644d2a730be/jm2c01360_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/05bdbbbbd605/jm2c01360_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/d68f7ea8f6d7/jm2c01360_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/a2fad23bc7f0/jm2c01360_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/964d42204d56/jm2c01360_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/4fd047250b90/jm2c01360_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/58c69f78ad9f/jm2c01360_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/d756cbc09fc1/jm2c01360_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/f88e7a4d89d8/jm2c01360_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/164fa7c8a45f/jm2c01360_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd7f/10041539/4a184a239aec/jm2c01360_0019.jpg

相似文献

1
Dipeptide-Derived Alkynes as Potent and Selective Irreversible Inhibitors of Cysteine Cathepsins.二肽衍生炔烃作为半胱氨酸组织蛋白酶的高效和选择性不可逆抑制剂。
J Med Chem. 2023 Mar 23;66(6):3818-3851. doi: 10.1021/acs.jmedchem.2c01360. Epub 2023 Mar 3.
2
Dipeptide-derived nitriles containing additional electrophilic sites: potentially irreversible inhibitors of cysteine proteases.含额外亲电位点的二肽衍生腈类化合物:半胱氨酸蛋白酶潜在的不可逆抑制剂。
J Enzyme Inhib Med Chem. 2009 Dec;24(6):1245-52. doi: 10.3109/14756360902797328.
3
Fluorescent nitrile-based inhibitors of cysteine cathepsins.基于荧光腈的半胱氨酸组织蛋白酶抑制剂。
Bioorg Med Chem Lett. 2012 Dec 15;22(24):7715-8. doi: 10.1016/j.bmcl.2012.09.086. Epub 2012 Oct 3.
4
Active Site Mapping of Human Cathepsin F with Dipeptide Nitrile Inhibitors.人组织蛋白酶F与二肽腈抑制剂的活性位点图谱
ChemMedChem. 2015 Aug;10(8):1365-77. doi: 10.1002/cmdc.201500151. Epub 2015 Jun 26.
5
Interaction of papain-like cysteine proteases with dipeptide-derived nitriles.木瓜蛋白酶样半胱氨酸蛋白酶与二肽衍生腈类的相互作用。
J Med Chem. 2005 Dec 1;48(24):7688-707. doi: 10.1021/jm050686b.
6
Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.新型非肽类氰胺作为人组织蛋白酶K和L的强效可逆抑制剂
J Med Chem. 2001 Jan 4;44(1):94-104. doi: 10.1021/jm0003440.
7
A comparative study of warheads for design of cysteine protease inhibitors.用于设计半胱氨酸蛋白酶抑制剂的弹头比较研究。
Bioorg Med Chem Lett. 2017 Nov 15;27(22):5031-5035. doi: 10.1016/j.bmcl.2017.10.002. Epub 2017 Oct 3.
8
Development of nitrile-based peptidic inhibitors of cysteine cathepsins.开发基于腈的半胱氨酸蛋白酶肽类抑制剂。
Curr Top Med Chem. 2010;10(3):294-322. doi: 10.2174/156802610790725452.
9
Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei.评估二肽腈作为布氏锥虫主要半胱氨酸蛋白酶罗德西亚蛋白酶抑制剂的作用。
Bioorg Med Chem Lett. 2017 Jan 1;27(1):45-50. doi: 10.1016/j.bmcl.2016.11.036. Epub 2016 Nov 15.
10
Highly selective azadipeptide nitrile inhibitors for cathepsin K: design, synthesis and activity assays.高度选择性的角蛋白酶抑制剂:设计、合成与活性测定。
Org Biomol Chem. 2013 Feb 21;11(7):1143-8. doi: 10.1039/c2ob26624e.

引用本文的文献

1
Development and Application of Reversible and Irreversible Covalent Probes for Human and Mouse Cathepsin-K Activity Detection, Revealing Nuclear Activity.用于检测人类和小鼠组织蛋白酶 K 活性的可逆和不可逆的共价探针的开发与应用,揭示核活性。
Adv Sci (Weinh). 2024 Oct;11(38):e2401518. doi: 10.1002/advs.202401518. Epub 2024 Jul 5.

本文引用的文献

1
Nitriles: an attractive approach to the development of covalent inhibitors.腈类:一种开发共价抑制剂的有吸引力的方法。
RSC Med Chem. 2022 Nov 7;14(2):201-217. doi: 10.1039/d2md00204c. eCollection 2023 Feb 22.
2
Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential.健康与疾病中的组织蛋白酶S(CTSS)活性——未开发临床潜力的宝库。
Mol Aspects Med. 2022 Dec;88:101106. doi: 10.1016/j.mam.2022.101106. Epub 2022 Jul 19.
3
Molecular Features of CA-074 pH-Dependent Inhibition of Cathepsin B.
CA-074 对组织蛋白酶 B 的 pH 依赖性抑制的分子特征。
Biochemistry. 2022 Feb 15;61(4):228-238. doi: 10.1021/acs.biochem.1c00684. Epub 2022 Feb 4.
4
Lysosomal peptidases-intriguing roles in cancer progression and neurodegeneration.溶酶体肽酶——在癌症进展和神经退行性变中的有趣作用。
FEBS Open Bio. 2022 Apr;12(4):708-738. doi: 10.1002/2211-5463.13372. Epub 2022 Feb 3.
5
Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy.蛋白酶触发的生物响应性药物递送用于恶性肿瘤的靶向治疗诊断。
Acta Pharm Sin B. 2021 Aug;11(8):2220-2242. doi: 10.1016/j.apsb.2021.01.017. Epub 2021 Jan 24.
6
OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space.OPLS4:改善化学空间挑战性领域的力场准确性。
J Chem Theory Comput. 2021 Jul 13;17(7):4291-4300. doi: 10.1021/acs.jctc.1c00302. Epub 2021 Jun 7.
7
The Tumor Proteolytic Landscape: A Challenging Frontier in Cancer Diagnosis and Therapy.肿瘤蛋白水解景观:癌症诊断和治疗的挑战性前沿。
Int J Mol Sci. 2021 Mar 3;22(5):2514. doi: 10.3390/ijms22052514.
8
Development of an F-Labeled Irreversible Inhibitor of Transglutaminase 2 as Radiometric Tool for Quantitative Expression Profiling in Cells and Tissues.开发一种 F 标记的不可逆谷氨酰胺转移酶 2 抑制剂作为放射性工具,用于细胞和组织中的定量表达谱分析。
J Med Chem. 2021 Mar 25;64(6):3462-3478. doi: 10.1021/acs.jmedchem.1c00096. Epub 2021 Mar 11.
9
Strecker-Derived Methodology for Library Synthesis of -Acylated α-Aminonitriles.用于合成α-酰化α-氨基腈库的施特雷克衍生方法。
ACS Omega. 2021 Jan 7;6(2):1328-1338. doi: 10.1021/acsomega.0c04908. eCollection 2021 Jan 19.
10
Crystal structure of Leishmania mexicana cysteine protease B in complex with a high-affinity azadipeptide nitrile inhibitor.墨西哥利什曼原虫半胱氨酸蛋白酶 B 与高亲和力的印苦楝肽腈抑制剂复合物的晶体结构。
Bioorg Med Chem. 2020 Nov 15;28(22):115743. doi: 10.1016/j.bmc.2020.115743. Epub 2020 Sep 6.